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ABSTRACT
This manuscript follows a single patient with pancreatic adenocarcinoma for
a five year period, detailing the clinical record, pathology, the dynamic evolution
of molecular and cellular alterations as well as the responses to treatments with
chemotherapies, targeted therapies and immunotherapies. DNA and RNA samples
from biopsies and blood identified a dynamic set of changes in allelic imbalances
and copy number variations in response to therapies. Organoid cultures established
from biopsies over time were employed for extensive drug testing to determine if this
approach was feasible for treatments. When an unusual drug response was detected,
an extensive RNA sequencing analysis was employed to establish novel mechanisms
of action of this drug. Organoid cell cultures were employed to identify possible
antigens associated with the tumor and the patient’s T-cells were expanded against
one of these antigens. Similar and identical T-cell receptor sequences were observed
in the initial biopsy and the expanded T-cell population. Immunotherapy treatment
failed to shrink the tumor, which had undergone an epithelial to mesenchymal
transition prior to therapy. A warm autopsy of the metastatic lung tumor permitted
an extensive analysis of tumor heterogeneity over five years of treatment and surgery.
This detailed analysis of the clinical descriptions, imaging, pathology, molecular
and cellular evolution of the tumors, treatments, and responses to chemotherapy,
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targeted therapies, and immunotherapies, as well as attempts at the development of
personalized medical treatments for a single patient should provide a valuable guide
to future directions in cancer treatment.

INTRODUCTION

one time point in the evolution of a tumor. This dynamical
study follows the changes in DNA sequences and DNA
sequence heterogeneity with time and treatment (albeit for
only a single patient). The DNA sequences obtained from
samples in the blood were compared to those sequence
changes found in the organoids made from biopsies taken
at different times. One of the important lessons learned
from these studies is that the DNA sequences, epigenetic
states, and properties of cancers evolve with time and
changing treatment protocols. Precision medicine aspires
to act upon the biological information about a tumor, to
craft an informed and intelligent treatment response. We
will have to learn how to obtain information about the
tumor rapidly, so as to intervene before the tumor changes
its basic information. This report reflects an attempt to do
just that.
The authors of this unusual research venture formed
a team to exchange biological samples, information, new
experimental protocols, and novel ideas and directions.
They often held joint meetings and phone conferences
to stay focused, organized, and informed about new
observations. They all sacrificed time and effort from other
research projects and activities, because they all came to
appreciate the rewards of helping an individual patient,
perhaps more directly than previous research avenues in a
laboratory had permitted.

On December 22, 2011, a patient was diagnosed
with an inoperable pancreatic adenocarcinoma. After
Folfirinox therapy, the tumor regressed and became
operable. It was removed on May 30, 2012. Eighteen
months later, metastatic lesions appeared in the lungs and
on the rib cage. It was at this point (Nov.1, 2013) that the
family decided to assemble a group of scientists who had
interest in and could carry out extensive surveillance of
the tumor in the patient and perform experimentation with
clinical materials collected from blood and biopsies of the
tumor tissue. The purpose of this was to inform and assist
the clinicians who were making the decisions about the
treatment and care of their patient.
The goals of this project were broader than the
care of a single patient: to follow a number of different
parameters during the dynamic evolution of a tumor in
a patient. This was accomplished by obtaining serial
biopsies and cancer cells and DNA from blood samples
over the entire time of treatment. A time line was created,
employing DNA sequencing from blood samples, the
production of three dimensional, or organoid, tissue
cultures and two-dimensional cell cultures, from serial
biopsies (as well as DNA and RNA sequencing of these
tissues) in order to follow the changes occurring during
treatments, and tumor response and progression (Figure 1).
Tumor heterogeneity was explored, detected, and followed
over time. Possible tumor antigens were identified from
biopsy samples and organoids. T-cell receptor sequences
were determined from the peripheral blood and the T-cells
located in tumor tissue. T-cells from the peripheral blood
of the patient were expanded with antigen exposure for
possible therapeutic choices. Attempts at making CAR-Tcells directed against an antigen observed on the tumor and
tested in the organoid cultures were explored. Organoid
cultures were employed to test for drug sensitivities in
cell culture and in mice and the results were compared
with expected sensitivities based upon DNA mutational
profiles observed in the tumors. When some unexpected
drug sensitivities were identified, an extensive RNA
sequencing analysis was carried out with tumor tissue
from mice treated with these drugs and possible pathways
involved in this treatment were elucidated.
Many of the experimental approaches described
here were carried out for the first time in cell culture using
biological materials directly or recently from a patient.
As such, they represent the forerunner of future paths
to be taken for the benefit of many patients. In addition,
these experiments addressed a limitation of past DNA
sequencing studies with tumor tissue, which explore only
www.oncotarget.com

CLINICAL BACKGROUND
A previously healthy, 50-year-old Jewish man
presented with intermittent back pain and epigastric
discomfort beginning in 8/2011. Computed tomography
of the abdomen in December 2011 revealed a 7.3 cm x 2.9
cm mass in the body of the pancreas, encasing the splenic
artery and extending along the celiac axis. The mass was
also abutting the proximal common hepatic artery and
superior mesentery artery. Endoscopic ultrasound with
fine needle aspirate of the pancreatic mass was performed
with cytology positive for adenocarcinoma. The patient’s
family medical history was notable for a sister with
breast cancer in her 60s and a father with prostate cancer.
Carbohydrate antigen 19-9 was within normal limits and
germline mutational testing was negative for a deleterious
BRCA 1 or 2 mutation. The majority of the patient’s
clinical care was coordinated between MD Anderson in
Houston and Siteman Cancer Center in St. Louis.
In light of the tumor’s extensive vascular
involvement, the patient was started on 5-FU, leucovorin,
oxaliplatin and irinotecan, FOLFIRINOX). After a total of
4 cycles of chemotherapy, there was radiographic evidence
of response. The patient received 1 more dose and he then
14765
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proceeded with chemoradiation. The patient received
gemcitabine-based chemoradiation to a total radiation
dose of 50.4 Gy with one dose of bevacizumab at the
initiation of radiotherapy and 2 weekly doses of cetuximab
as radiation completed. The patient tolerated the treatment
well, and follow-up CT imaging revealed significant tumor
regression. Tumor shrinkage was seen on repeat imaging.
The patient was referred to the Medical College of
Wisconsin and underwent an R0 distal pancreatectomy
and splenectomy; the common hepatic artery was spared.
Pathology confirmed a stage IIA (T3N0M0) pancreatic
cancer with significant treatment-effects response. The
patient’s post-operative course was uneventful, followed
by two months of adjuvant therapy comprised of
gemcitabine, capecitabine and nab-paclitaxel.
Close radiographic and clinical surveillance for
relapse revealed no evidence of disease until November
2013, 18 months postop. At that time, small lung lesions
and a rib lesion were noted. The patient and his family
assembled a team of clinicians and scientists that could
provide further expert clinical guidance and devise
scientifically sound novel therapeutics. Thorascopic
wedge resection of a left lung lesion confirmed metastatic
disease with residual tissue used to create organoids and
patient derived murine xenografts. The patient resumed
FOLFIRINOX treatment along with denosumab. The
patient had a minor radiographic response to therapy and
after 4 months of therapy, he was placed on maintenance

infusional 5FU with disease remaining stable through
November 2014. During this interval, single cell analysis
from tumor derived organoids demonstrated amplification
of HER2 and the patient was tried on capecitabine plus
trastuzumab. Tumor progression was documented after a
6-week course of therapy.
In February 2015, shortly after a brief chemotherapy
holiday, the patient presented with shortness of breath
caused by a new onset of right pleural effusion. Malignant
cells were seen in the pleural fluid. FOLFIRINIX was
resumed with the addition of bevacizumab. Bevacizumab
was discontinued after asymptomatic pulmonary embolism
was noted. Anticoagulant therapy was initiated and
FOLFIRINOX was continued. By June 2015, the patient
had disease progression in the lung, and he was started
on gemcitabine and nab-paclitaxel with paricalcitol.
The patient had a minor response to gemcitabine, nabpaclitaxel, and paracaltriol for 2 months with progression
after 2 more months of treatment.
In October 2015, the patient enrolled in a clinical
trial at MD Anderson, which administered autologous
T-cells enriched for reactivity to VMMR-1. A non-mutated
antigen was found, based on organoid peptide analysis.
Based on the study protocol, he received Cytoxan,
followed by T cell infusion, then subcutaneous IL-2
injections and pembrolizumab. The patient experienced
significant weight loss and fatigue during the therapy.
He required frequent therapeutic thoracenteses for

Figure 1: Patient clinical course throughout a four year period. Size of lung and pleural metastatic lesions were used to
determine response to therapies (left axis). CA-19-9 levels are plotted, although remain mostly within normal range (right axis).
www.oncotarget.com
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palliation of dyspnea. A repeat CT scan of the chest in
11/2015 showed rapid disease progression, manifested
as an interval increase in lung lesions and pleuralbased metastatic disease. Surprisingly, the biopsy of a
pleural-based nodule revealed a poorly differentiated
neuroendocrine tumor.
In light of the rapid disease progression, a
combination of 5-FU, gemcitabine, docetaxel and cisplatin
was initiated on 12/14/2015. The patient’s respiratory
status deteriorated and he was intubated two days later.
Concern of an acute inflammatory response was raised,
and high dose steroid therapy was instituted. A similar
chemotherapy regimen was administered two weeks later,
and the repeat CT revealed stable pleural caking and

lung metastatic lesions. Although tumor stabilization was
achieved with resumption of cytotoxic chemotherapy, he
remained with restrictive lung disease and he opted for
a tracheostomy for persistent hypoxemia and hypercarbic
respiratory failure requiring mechanical ventilation. He
had clear mentation with intact organ functions.
On January 6, 2016, the patient was transferred
to Barnes Jewish Hospital in St. Louis. He was treated
with carboplatin and etoposide for poorly differentiated
neuroendocrine tumor histology. Therapy was delivered in
an intensive care unit, and he subsequently transferred to
an immediate care floor for ventilator care given his stable
clinical condition. A repeat FNA of the pleural lesion
was performed and cytology revealed mixed histology

Figure 2: H&E staining of lung metastatic biopsy taken at the beginning (left) and end (middle and right) of liquid
biopsy follow up. Histological analysis demonstrates a phenotypic change from adenocarcinoma to small cell-like tumor. Rapid autopsy
samples show phenotypically distinct lesions comprising neuroendocrine and ductal-like histologies.

Figure 3: Treatment monitoring for a metastatic PDAC patient with 15 liquid biopsies. The graph illustrates the rise and fall
of molecular and clinical indicators in the context of cancer treatments.
www.oncotarget.com
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malignancy with predominant neuroendocrine tumor in
addition to features of adenocarcinoma. Meanwhile, the
patient had suffered a ventilator-related tracheostomy
infection, pneumonia, fungal infection and bilateral lower
extremities DVT. His clinical condition declined over the
hospital stay despite normal neurocognitive function and
adequate cardiac, renal, and hepatic function. The patient
requested ventilator support be withdrawn and he expired
shortly thereafter, 50 months from his initial diagnosis of

pancreatic cancer.

Evolving genomic landscapes of a metastatic
PDAC patient through liquid biopsies and multiregion sequencing
Fifteen months after the wedge resection, the patient
began to be monitored by the liquid biopsy program at

Figure 4: Heatmap of COSMIC mutations detected across tissue samples. Only those mutations present in at least two distinct

lesions were considered based on a consensus approach. TB1 and TB2 corresponds to a wedge and core biopsy acquired on 12/2013 and
12/2015 respectively. TB4-TB13 are tissues acquired from rapid autopsy on 02/2016.
www.oncotarget.com
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KRAS and TP53 mutations as surrogates of
patient tumor burden

MD Anderson in the Maitra lab. A total of eighteen
liquid biopsies (15 peripheral blood and 3 malignant
pleural effusions) were performed throughout disease
progression and therapeutic intervention, which include
chemotherapies, targeted therapies, and immunotherapies.
Subsequently, the patient underwent a second lung biopsy
(a core needle biopsy). The core needle biopsy (CNB)
was histologically determined to be a metastatic neoplasm
with high-grade neuroendocrine features (Figure 2). At the
time of death, rapid autopsy was performed on the patient,
at which point seven spatially distinct lung metastatic
lesions acquired for molecular analysis. Disease response
was primarily determined by CT imaging as the standard
clinical biomarker, CA-19-9, remained within normal
ranges throughout disease course. The tissue and liquid
biopsies were utilized as an ancillary decision support for
this patient, as follows:

Next-generation sequencing (NGS) analysis of
both the patient’s initial metastatic tumor (histologically
consistent with an adenocarcinoma) and second lung
metastasis (histologically consistent as a high grade
neuroendocrine carcinoma) samples harbored oncogenic
KRAS G12D and TP53 R175H mutations, along with
several truncal genomic imbalances, with concordant
changes in gene expression (ERBB2, FOXO1, KLK2,
NRAS, DAXX, HMGA1 and NOTCH2 amplifications and
a FHIT deletion) suggesting that the metastatic small cell
carcinoma was not a new primary tumor, but rather an
evolution of the original metastatic PDAC.
Since KRAS represents a reliable tumor burden
surrogate for PDAC (seen in close to 95% of PDAC)

Figure 5: Detection of allelic imbalance events by hapLOHseq across sequenced tissue samples. Representative events are
highlighted to depict distinct patterns of chromosomal aberrations across tissue sites.
www.oncotarget.com
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Landscapes of genomic
metastatic tumor tissue

it was decided to perform ultrasensitive droplet digital
PCR (ddPCR) in the complete series of 15 blood based
liquid biopsies [1]. Mutation allele frequencies (MAFs)
of the driver KRAS in both the exosomes-derived DNA
(exoDNA) and circulating cell-free DNA (cfDNA) were
plotted against clinical covariates (Figure 3). The MAFs
for both compartments trended with patient tumor burden,
including size of the pulmonary metastases (sum of the
largest dimension, “SLD” according to RECIST 1.1
criteria), suggesting that these mutations are representative
of tumor burden. Notably, the tumor burden (as determined
by exoDNA and cfDNA mutant KRAS allele fraction) rose
from non-detectable to detectable levels when therapy was
changed from FOLFIRINOX to Gemcitabine/Abraxane,
and thereafter, sharply spiked after the patient received
adoptive T-cell therapy, finally regressing once the
patient resumed cytotoxic chemotherapy comprised of a
“cocktail” of agents, including cisplatin, carboplatin and
etoposide (amongst others).

heterogeneity

in

At the time of death, rapid autopsy retrieved seven
warm biopsies of the lung tissue metastasis, representing
distinct spatial lesions, with the goal of determining
patterns of heterogeneity. Tumor regions were separated
by a margin of at least 0.5cm in order to be considered
a spatially distinct lesion, and were compared to the two
prior biopsy samples (Figure 4 TB1 and TB2). Significant
heterogeneity among putative subclonal driver mutations
began to accumulate over time, and these were partially
shared across tissue samples. These included mutations
in STK11 and NOTCH2, which have been previously
described to have a role in PDAC carcinogenesis, and a
secondary mutation in TP53, which may have been related
to selective pressures induced by this patient’s prolonged
therapeutic history [2, 3].

Figure 6: Heatmap of detected copy number variations detected across tissue samples. Only CNVs previously associated

to PDAC related core pathways are represented based on previous ICGC and TCGA data. Red = amplification, Blue = deletion, and Grey
= no CNV.
www.oncotarget.com

14770

Oncotarget

Allelic imbalances

genome.

Copy number aberrations

Identification of chromosomal allelic imbalance (AI)
may indicate ongoing chromosomal instability, and can be
inferred through whole exome sequencing. As a result of
chromosomal deletions or duplications, AI profiles provide
insights into patterns of tumor progression, with potential
correlates to prognosis and therapeutic actionability.
In order to overcome the challenges of detecting subtle
chromosomal AI, due to diluted tumor fractions such as
those seen through liquid biopsies, the MD Anderson
team applied a methodology known as hapLOHseq [4].
In doing so, they sought to identify unique temporal and
spatial patterns of AI in distinct biopsies taken throughout
a more than two-year period. As depicted in Figure 5,
they observed pre-existing AI events on chromosomes 2
and 11, present since the wedge biopsy (genomic regions
shaded in yellow) taken from 2013, but spatially diverse
in subsequent multiregion whole exome sequencing two
years later. Further events on chromosomes 10 and 15
(shaded in blue) demonstrate the emergence of aberrations
that may be directly related to the evolution of this tumor

Although progression of PDAC has been suggested
to occur over a period of nearly two decades, affording
a window of promise for early detection biomarkers,
recent studies have suggested that rather than a step-wise
molecular sequence of aberrations, PDAC tumorigenesis
may follow a model similar to what is termed punctuated
equilibrium [5]. Specifically, it is possible that most
mutations accrue in an extended phase under preneoplastic tumor development, but a single transformative
event, which may be influenced by genomic instability
from copy number variations (CNVs), induces a
transformative effect facilitating overt metastasis. This
underlies the functional importance of CNVs in the PDAC
tumorigenesis and potential mechanisms of therapeutic
resistance. Thus, patterns of copy number evolution
were studied over time to determine if these events
were related to disease status. As depicted in Figure 6,
significant heterogeneity of copy number changes is

Figure 7: Mutation patterns were defined for each tumor sample using inferred exome sequencing mutations. These
signatures were then decomposed into putative combinations of known mutation signatures (using COSMIC mutation signatures), where
signatures 3, 4 and 6 were highly prevalent across the tissue samples and have previously been associated with deficiencies in DNA-doublestrand break repair, exposure to tobacco carcinogens and defective DNA mismatch repair respectively.

Figure 8: A. The biopsy is a CNB with a lot of crush artifact, but PARP IHC seems strongly positive as compared with a known positive

control of a human SCLC. B. (Thermo cat# RB-1516-P, rabbit polyclonal, 1:100). Panel C. represents a negative control without primary
antibody.
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present among previously identified PDAC related core
signaling pathways [1, 6-8]. CNVs present in the initial
wedge biopsy appear to be rare among PDAC related core
pathways, although it is important to note the identified
amplification in ERBB2, which led to targeted therapy
selection using Trastuzumab, to which the patient did not
respond. Subsequent tissue profiling through a core biopsy
showed that the patient’s tumor harbored amplification and
overexpression in the EGFR gene, potentially providing a
resistance mechanism to this therapy.
With tumor progression, clonal aberrations appeared
among KRAS and CDKN2A, as well as genes related to
SWI/SNF mediated chromatin remodeling. Of particular
interest, is the emergence of MYC amplifications detected
in all rapid autopsy lesions. Although this was not found
in the core biopsy two months prior, it is possible that
this CNV was missed due to limited sampling of spatial
heterogeneity from a single core biopsy. A greater
degree of heterogeneity appears to be present among
axon guidance and other oncogenic pathways, which
include amplifications and deletions of the same gene
across spatially distinct tissue samples (ROBO1 and
GATA6). Spatial heterogeneity among tissue samples also
exists in genes such as PIK3CA. Of note is a significant
amplification of DNA damage repair genes (BRCA1
and BRCA2), which may be related to compensatory
mechanisms of DNA repair in an unstable genomic
background. It is important to note, however, that
distinguishing evolutionary copy number events from
stochastic aneuploidy may be challenging, underlining the
importance of observing such events in a relevant context.

COSMIC mutation signature 3, which is associated
with deficiencies in DNA-double-strand break repair,
and signature 6, which is associated with defective
DNA mismatch repair. This BRCAness signature is
putatively associated with DNA Damage Repair (DDR)
aberrations in cancers, for which DNA damaging drugs
may prove effective, such as platinum compounds like
cisplatin and oxaliplatin, or PARP inhibitors. Tumor
tissue profiles experienced an increase in load of genomic
aberrations (specifically, structural variations) over
time, suggestiing that the patient’s tumor was, in fact,
DDR deficient. Correlated to this hypothesis, the patient
consistently responded to therapies involving platinum
based chemotherapies such as FOLFIRINOX and readily
progressed when switched to Gemcitabine based regimens.

PARP overexpression underscores a state of
ongoing DNA repair defect
To further elucidate whether alternative DNA
repair mechanisms were active in the tumor, RNA
sequencing analysis was performed on the last core
biopsy, demonstrating high expression of PARP (128.62
TPM) in the tumor (6 fold more expressed than normal
pancreas in TCGA). Furthermore, immunohistochemical
analysis confirmed PARP overexpression within the
high-grade neuroendocrine tumor compartment (Figure
8). Overexpression of this protein is seen in a variety
of cancers, and can be associated with poorer overall
survival. Moreover, PARP overexpression, in the context
of cancer harboring mutations in DDR pathway, leads
to the option of using PARP inhibitors as a potential
therapeutic strategy. Further evidence supporting this
hypothesis comes from the noticeable, albeit transient,
reduction in tumor burden, upon administration of a
cisplatin-containing regimen (Figure 8).
The MD Anderson studies show the potential
clinical utility of liquid biopsies for the monitoring and
clinical guidance of an advanced PDAC patient. They

Inferring mutational signatures in PDAC
Elucidation of mutational signatures across tissue
samples revealed the presence of previously described
“BRCAness” mutational patterns, which are representative
of unstable genomes (Figure 7) (1). Signatures that likely
are a consequence of DNA repair deficiency include

Figure 9: Isolation of hM1 cultures from a lung metastasis. hM1 cancer cells were isolated and grown as a three-dimensional
organoid A., and adapted to monolayer culture B. Cancer associated fibroblast (hM1-CAF) were isolated as a monolayer culture C. (Scale
bars = 200 µm).
www.oncotarget.com
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Organoids, cell lines, sequencing and therapeutics

demonstrate that circulating MAFs of driver mutations
can be representative of tumor burden and that these
values correlate with clinical response. These molecular
measures are shown to be especially useful in the case of
the subject patient, where CA19-9 (a traditional tumor
burden measure) was within normal ranges during the
majority of his care. The studies demonstrate the temporal
and spatial genomic landscapes of this patient’s tumor,
identifying arising putative driver aberrations in the form
of single nucleotide variants, copy number changes, and
gross chromosomal imbalances, depicting the inherent
heterogeneity that is present within PDAC. Based on these
molecular signatures, it is subsequently possible to select
for candidate therapies that may be most beneficial to the
patient.

Following the surgical resection of the lung
metastasis and the confirmation of pancreatic
adenocarcinoma by pathologists at MD Anderson Cancer
Center, the Tuveson lab at Cold Spring Harbor Laboratory
received four different biopsy specimens, each consisting
of multiple tissue fragments. Each sample contained
differing contributions of tumor and normal cells and
was processed independently as a different sub-line of
human metastatic organoid 1 (hM1) (labeled A - D). These
samples were used to prepare organoids, and a small
portion was formalin fixed and paraffin embedded for
independent validation of neoplastic content and cellular
composition. Within 48 hours, small organoids were

Figure 10: Histologic analysis of hM1 organoids. Representative images of the different morphologies by H&E A., C., F. and
Alcian Blue/Mucin-production stain B., D., E. (Scale Bar = 50µm).
www.oncotarget.com
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detectable in each individual isolate. Upon passaging, the
Cold Spring Harbor Laboratory team began evaluating
modifications of the basal media using parameters that

were being established for human normal and tumor
pancreatic organoid lines [9]. This optimization allowed
exponential expansion of the hM1 organoids (Figure 9).

Figure 11: hM1 DNA copy number analysis heatmap. Single cells derived from organoids at passage 6 and 8, and from monolayer
culture at passage 2 were analyzed for DNA copy number (CN) gain or loss. The predominant clonal features appear in all three cultures
(*), while normal-like cells are only present in early passages of the organoid cultures (**).
www.oncotarget.com
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In parallel to organoid isolation, a cancer-associated
fibroblast line (hM1-CAF) and an organoid-derived 2D
cancer cell line (hM1-2D) were established. Generation
of a monolayer cell line directly from the patient specimen
failed. In addition, patient derived xenografts were
established from four fragments from which one tumor
engrafted and was passageable following six months
of growth in vivo. The morphology of the organoids
consisted of both single- and multi-layer spheroids (Figure

10), similar to previously generated human organoid lines.
Although the patient did not exhibit serological elevation
of the pancreatic cancer biomarker, CA19-9, it was
highly expressed in the organoids, using flow cytometry
and immunoblot (data not shown). The findings suggest
that this biomarker is expressed by the tumor cells, but
not shed in large amounts, as observed in some PDAC
patients.
To better assess the heterogeneity of the hM1

Figure 12: Copy number analysis of hM1. A. Copy number analysis of a representative single cell clone of hM1. B. Copy number
of primary metastatic tissue after laser dissection (~40% neoplastic cellularity).
www.oncotarget.com
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Figure 13: High throughput therapeutic screen of hM1 cells identifies high efficacy targeted inhibitors. Growth inhibition

effect in hM1 cancer cell line A. and in cancer associated fibroblasts B. in response to 3200 approved agents. Dose response curves for
cytotoxic chemotherapeutics C. and D. and selected targeted inhibitors in therapeutic screen E. and F.
www.oncotarget.com
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organoid culture and to discern potential therapeutic
avenues, copy number analysis (CNA) was at the single
cell level. To account for potential genetic selection in
the cultures, analysis was performed on hM1A organoids
at two different passages, as well as cells derived from
a monolayer culture of hM1A that were established
using early passage organoids. This experiment tested
48 single cells derived from two different passages of
the organoid culture and compared them to 48 cells
grown as a monolayer. DAPI-stained DNA from single
nuclei was amplified and analyzed using next generation
sequencing to determine copy number variation (Figures
11 and 12A). This analysis revealed that hM1A organoid
cultures are oligoclonal and display distinct gene copy
number gains and losses, which are recapitulated both in

2D and 3D cultures. The single cell CNA of organoids
mirrors the genetic analysis performed at the University of
Michigan using frozen metastatic tissue and also reveals
distinct and numerous copy number alterations that are not
apparent in bulk tumor analysis. (Figure 12A and 12B).
The method provides a highly detailed genomic landscape
that illustrates which molecular mechanisms are altered
in the tumor. For instance, the complete loss of RB and
the amplification of Cyclin E1 would lead to a loss of the
G1/S cell cycle checkpoint. In addition, the Cold Spring
Harbor Laboratory Team study predicts a strong activation
of the Mitogen-Activated Protein Kinase pathways, given
that KRAS, EGFR, and HER2 are amplified (4.95, 3.79,
and 3.05 copies per cell on average, respectively).
The ultimate goal of the Cold Spring Harbor Lab

Figure 14: Thoracentesis-derived cell lines hM1P1 and hM1P2 contain KRAS-G12D genetic lesion. Lung metastasisderived hM1A-2D A. is show next to thoracentesis-derived hM1P1-2D and hM1P2-2D cell lines C. & D. All three cell lines contain the
KRAS-G12D mutation (targeted sequencing of KRAS shown in inset). When received from the clinic, the pleural effusion contained a
majority of mesothelial cells B. (Scale bar = 200 µm).
www.oncotarget.com
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team was to identify and exploit potential therapeutic
strategies against hM1 organoids. The single cell CNA
highlighted CDK and the ErbB pathway as potential
therapeutic targets. The CSHL group also initiated
collaboration with the Scripps Research Institute High
Throughput Screening (HTS) core to empirically discover
additional therapeutic approaches. The goal of the
collaboration was to perform unbiased screening of FDAapproved compounds that could be rapidly applied in the
clinic. The Scripps Institute compiled a library of ~3200
compounds using approved agents in the USA, Europe,
and Japan, and employed a pipeline amenable to HTS
in monolayer cultures. Cold Spring Harbor Laboratory
designed a screening approach to maximize the discovery
of compounds selectively cytotoxic to hM1 cancer cells
and fibroblasts by including both the hM1 monolayer
cell line and the hM1-CAF (cancer-associated fibroblast)
line (SV40 immortalized). The cells were adapted to
a 1536-well plate format and the primary screening
against the compound library given at a single dose was
performed. 23 highly-cytotoxic agents achieved more than
80% inhibition of hM1-2D growth in the screen (Table
1). Five additional drugs were specifically evaluated
because they would be part of standard of care or could
potentially target hM1 genetic vulnerabilities such as
the amplification of the ERBB receptor tyrosine kinase
family. The team selected compounds for secondary
screening and full dose response assay (Figure 13), and
identified a small subset of hM1-selective cytotoxic
and targeted agents. The MEK inhibitor Trametinib
was one of the most potent and selective agents, with

an observed EC50 of 19 nM. As previously suspected,
with amplification of EGFR and HER2 in hM1 cells, the
pan-ErbB inhibitors, Afatinib, and Neratinib, were very
effective against hM1 cancer cells. The identification of
molecular targets in the ErbB and MAPK cascade is not
surprising in a KRAS mutant cancer cell [10]. Disulfiram
was also identified as an unexpected compound with
high activity against hM1 with an observed EC50 of 316
nM. Disulfiram is currently prescribed in the USA as a
treatment for chronic alcoholism due to its inhibition of
acetaldehyde dehydrogenase [11]. Surprisingly, Disulfiram
was also identified as a top hit in HTS assays against
prostate and breast cancer cell lines [12, 13], and many
anti-cancer activities in various cancer types have been
described, such as proteasome inhibition [14, 15, 16, 17].
Additionally, the proteasome inhibitor Bortezomib is also
a potent cytotoxic for hM1- 2D and hM1-CAF, and does
not provide selective effect on the cancer cells.
Throughout the clinical care of the patient,
repeated biopsies allowed generation of additional
organoid and cell line cultures. Two independent
thoracenteses were performed at the Washington
University Hospital in St. Louis and at MD Anderson in
Houston (early 2015). The Cold Spring Harbor Laboratory
team received a pleural effusion sample from each medical
institution and generated two hM1P (pleural) organoid
and monolayer cell lines (Figure 14). They observed that
Trametinib, Neratinib, and Disulfiram maintained their
activity in the newly generated hM1P cell lines, whereas
the chemotherapeutic gemcitabine was now less active,
hinting at an acquired resistance to ongoing therapy

Figure 15: Therapeutic testing of hM1 monolayer cells. Cytotoxicity of various compounds at 2 different concentrations on hM1
monolayer cell lines.
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(Figure 15).
To validate targeted therapeutic strategies, the
CSHL team generated hM1A mouse xenografts. The
genetic alterations present in hM1 organoids, such as the
KRAS-G12D and TP53-R175H mutations, render hM1A
cells very aggressive when transplanted orthotopically
into the pancreas of immunocompromised mice (Figure
16). Large desmoplastic tumors grew in the pancreas of
the mice, and a high frequency of lung metastasis with
remarkable recapitulation of the histopathology of the
primary metastatic tissue was observed (Figure 16). The
acquired resistance to chemotherapy seen in hM1P cells
highlighted the need for targeted therapeutic options for
the patient, therefore, a subset of regimens in the hM1A
orthotopic xenografts was tested. The regimens tested

included Disulfiram, Trametinib, and the combination of
both agents (Figure 17). Whereas single agent Disulfiram
did not induce a tumor regression, the MEK inhibitor
Trametinib did lead to tumor regression in 2/6 mice. The
combination of both agents led to the largest effect on
tumor burden, with more substantial tumor regressions
observed in 4/6 mice, indicating that potentially these
compounds could have been beneficial to the patient. Yet,
some mice did not respond to the combination (2 out of
6), highlighting the possible impact of oligoclonality on
therapeutic response.
After the patient was hospitalized with highly
progressive disease in early 2016, a core needle biopsy
obtained from the Washington University Hospital in St
Louis was used to generate a novel organoid line hM1E.

Figure 16: hM1 orthotopically grafted organoid (OGO) recapitulate human tumor histopathology. Two representative
H&E images of the patient’s lung metastatic tissue A. compared to large desmoplastic and mucinous mouse pancreatic tumors B., and
mouse lung metastases C. (Scale bar = 100 µm).
www.oncotarget.com
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Shortly thereafter, the patient passed away with a large
tumor burden. Tissue was received from the rapid autopsy,
from which was generated one final organoid line (hM1F).
All of these cancer models maintained the original
KRAS-G12D mutation (data not shown). To understand
the drug resistance and sensitivity changes over time in
serial organoid cultures, the activity of standard of care
chemotherapeutic compounds and targeted agents in
the hM1 organoid series was determined (Figure 18).
Although the chemotherapeutic cytotoxic agents display
activity in the early organoid hM1A, they lose their
potency in the late hM1E biopsy and the autopsy-derived
hM1F organoids. Furthermore, targeted agents such as
Bortezomib and Afatinib are also less effective in the
late-disease derived organoids. Some compounds do not
display a change in activity, such as Selumetinib and
Olaparib. The response observed in the organoids mimics
the resistance observed in the patient with advanced
disease, indicating that the organoid system may represent
a robust system for precision medicine. Intriguingly, the
testing results using the mTOR inhibitor Everolimus
demonstrate increased sensitivity in hM1E and hM1F.
This is in line with the pathological findings that the

pancreatic ductal adenocarcinoma phenotype switched
into a poorly differentiated small cell-like, neuroendocrine
state. Pancreatic neuroendocrine carcinomas are known to
be responsive to mTOR inhibition [18, 19], suggesting
that MTOR inhibition might have been a viable clinical
strategy.

RNA and drug profiles
The Rinn lab at Harvard performed a molecular
profile to understand how the tumor, hM1, responded to the
top drugs screened by the Tuveson group at Cold Spring
Harbor Laboratory. Specifically, the Rinn lab focused on
Trametinib and Disulfiram, the former being administered
to the patient, and the latter showing important synergistic
effects in tumor reducing capabilities in the screen. The
goal was to profile the entire transcriptome for generegulatory changes of mRNA, and the possible roles
of long noncoding RNAs as an unexplored area. hM1
PDX models treated with Trametinib and Disulfiram
(at a dosage of 3mg/kg, and 80mg/kg respectively)
were analyzed in parallel with a vehicle control. The

Figure 17: hM1 OGO mouse therapeutic study of selected compounds. Response to therapy quantified by ultrasound of the
tumor before and after treatment in Immuno-compromised mice (NSG) orthotopically grafted with hM1 organoid tumor pieces.
www.oncotarget.com
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organoid treatment was performed by the Tuveson lab in
quadruplicate (triplicate for Trametinib). After 7 days of
exposure, tumors were harvested and snap frozen. The
Rinn lab then isolated total RNA and prepared sequencing
libraries (TruSeq, Illumina) for massively parallel RNA
sequencing. The samples were sequenced on a HiSeq with
an average depth of 39.8 million reads per replicate (437
million reads total; 50bp reads, paired-end sequencing).
Finally, differential expression analyses (methods) were

performed to determine genes that were significantly up
or down regulated in Trametinib and Disulfiram relative
to vehicle control.
The largest impact was observed on transcriptional
regulation in the Disulphiram-treated samples, with a
total of 396 mRNA genes differentially regulated (145 up
and 251 down) in treated vs. vehicle control. In contrast
to Disulfiram, in the Trametinib-treated samples, only 93
mRNA genes were misregulated (48 up and 45 down)

Figure 18: Therapeutic testing of hM1 organoid cultures. Dose response assay with hM1A (blue lines), hM1E (red lines), and
hM1F (green lines) organoids, for chemotherapeutic agents and targeted agents.
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14781

Oncotarget

Figure 19: Transcriptional analysis of top drug targets. A. Significantly dysregulated mRNA genes in either Disulfiram-vehicle

or Trametinib-vehicle. Log2 fold change of each replicate is shown relative to vehicle replicate 0. B. Significantly dysregulated lincRNA
genes. Log2 fold change of each replicate is shown relative to vehicle replicate 0. C. Reactome gene ontology enrichment (BH adjusted
p-value < 0.01) for genes significantly dysregulated in disulfiram samples. D. Log2 fold change of PI3K pathway genes in each sample
relative to vehicle replicate 0. E. Expression in FPKMs of TNS4. F. Expression in FPKMs of lincRNA RP5-1028k7.2. G. Raw RNAseq
read pileup across the RP5-1028k7.2 locus, with gene structure shown above.
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relative to the vehicle control (Figure 19A). Interestingly,
it was possible to detect differential transcription of 24
lncRNAs (21 differentially expressed in Disulfiram-treated
samples and 3 in Trametinib-treated samples, Figure
19B). The Rinn lab next performed gene ontology (GO)
enrichment analyses to determine if there were trends in
specific gene pathways or processes that were commonly
mis-regulated. They were unable to find coherent gene
expression changes in the Trametinib experiments (data
not shown) but found a clear signature of PI3 Kinase
pathway regulation in the Disulfiram-treated samples
(Figure 19C). They further investigated the specific genes

defining this signature and found that the vast majority
were down-regulated (Figure 19D). Together, these
analyses suggest that Disulfiram may strongly downregulate PI3K signaling in tumors.
The Rinn lab next looked for long noncoding RNA
(lncRNA) regulation with a particular focus on lncRNAs
that are mis-regulated in Disulfiram-treated samples. They
also looked for lncRNAs neighboring mRNA genes that
showed coherent down-regulation, potentially implicating
the lincRNA in cis regulation of the mRNA at that locus.
Such a gene expression pattern would provide a new
avenue of therapeutic intervention—targeting the lncRNA

Figure 20: The number of DNA sequence reads of T-cell receptors from the total leukapheresis (sample 1) and from
the metastatic lung tumor (TP_2047(y), obtained Nov. 2013) (sample 2). The high clonal counts of T-cell receptor sequences from
the leukapheresis (in blue) and from the tumor (in orange) are presented and the sequences that are expanded clonally in both samples are
in the upper right corner of the graph.
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Target determination and adoptive cell transfer

to down-regulate the neighboring mRNA. Indeed, they
found the lncRNA RP5-1028K7.2 to be significantly
down-regulated in Disulfiram-treated samples with a
concomitant down-regulation of the neighboring mRNA
TNS4, an emerging oncogene with ties to PI3k signaling
through stabilization of c-MET [20, 21] (Figure 19E-19G).
This regulatory perturbation was not observed in
Trametinib samples. Collectively, the molecular profiling
of PDX models of hM1 suggests a potential explanation
for Disulfiram’s ability to reduce tumor volume — through
reduction of PI3K signaling [22, 23], and potentially
through modulation of the noncoding transcriptome.
Reads were aligned to the human genome (hg19)
using hisat (with non-standard options -p 8 —qc-filter)
and GENCODE annotation (v19, filtered for lincRNAs,
processed transcripts, and protein coding genes) [24, 25].
Bams were quantified using cuffquant and differential
expression analysis was performed with cuff diff using
non-standard options -p 10, and a contrast sheet defining
comparisons between Trametinib-vehicle, and Disulfiramvehicle [26]. All analyses were performed using
cummerbund and other packages from bioconductor [27,
28].

For antigen discovery, the Yee lab at MD Anderson
expanded patient-derived tumor cells (hMIA-2d) to
approximately 108 cells (10 x 10 cm confluent plates), then
lysed them using Triton X-100. Cell lysates were incubated
overnight at 4°C with gentle agitation with 1 ug HLA-A,
B, C specific mAb W6/32 for every 10 mg protein. Protein
A/G Ultralink resin beads were used to immunoprecipitate
HLA molecules, which were then directly eluted along
with tumor-associated peptides using 0.1N acetic acid
in five consecutive 1 mL eluates. Purification of HLA
was confirmed by Western Blot analysis and HLApositive elutes were pooled and analyzed by tandem
mass spectrometry (MS/MS), as described below. For
discovery phase MS/MS, eluted HLA-bound peptides
were injected onto a high-sensitivity HPLC system
(Dionex 3000 RSLC), separated by reversed-phase
chromatography in 0.1% formic acid water-acetonitrile on
1.8 micron C18 (Agilent Technologies) and analyzed on
an Orbitrap Elite mass spectrometer (Thermo Scientific)
using data-dependent acquisition. The Mascot algorithm
was employed to search acquired MS/MS spectra

Figure 21: The number of DNA sequence reads of T-cell receptors from the T-cell product of the peptide amplification
of the total leukapharesis (sample 1) and from the leukapheresis (sample 2). The high clonal counts of T-cell receptor sequences
from the T-cell product of peptide expansion (in blue) and the leukapharesis (in orange) are presented and the sequences that are high clonal
DNA sequence reads in both samples are in the upper right-hand corner.
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against the SwissProt complete human protein database
using 10 ppm parent mass tolerance, 0.8 d fragment ion
tolerance, Met oxidation, no enzyme selectivity. Search
results were cross-referenced with the appropriate MHCbinding specificities using the NetMHC 3.4 algorithm.
Approximately 1800 peptides were detected in Discovery
phase MS/MS, all corresponding to wild-type sequences
matching proteins within the human proteome.
Based on the results of Discovery MS/MS,
whole exome sequencing, and bioinformatics analysis
considering target gene expression in normal tissues
(GTex RNAseq databases), human pancreatic tumors
(TCGA RNAseq database), and the patient’s own RNAseq
analysis, 11 isotope- labeled high-confidence peptides of
interest (8 mutated and 3 non-mutated) were synthesized
and used as standards in a more sensitive targeted MS/
MS analysis. In this analysis, retention-time windows
for the synthetic peptide standards of interest were pre-

determined by MS analysis of the synthetic peptides, then
targeted methods for searching tumor-associated peptides
were constructed using mass windows of 3 Da around
each m/z. The targeted MS/MS experiments verified the
presence of all 3 non-mutated peptides, but convincing
MS evidence was not found for any of the predicted
mutated peptides.
Generation of pancreatic antigen-specific CTL for
adoptive therapy
Following identification of the 3 epitopes
corresponding to pancreatic cancer-associated antigens
(PCAA), clinical grade peptide and peptide-MHC
tetramers were synthesized and used to generate PCAAspecific CTL. All clinical investigations were conducted
according to the Declaration of Helsinki principles.
The patient was enrolled on an approved protocol. The
generation of antigen-specific CTL was performed
according to methods established in the Yee Lab [29, 30].

Figure 22: The number of DNA sequence reads of T-cell receptors from the T-cell product of the peptide amplification
(sample 1) and from the metastatic lung tumor (sample 2, TP_2047(y)). The high clonal counts of T-cell receptor DNA
sequence reads from the T-cell product (in blue) and the metastatic lung tumor (in orange) are presented and the two blue sequence clones
in the upper right corner of the graph are in common and in high amounts in both the amplified T-cell clones (Oct, 2015) and the tumor
(Nov, 2013).
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Table 1: 23 top hits that show >80% inhibition and 5 additional compounds of interest
hM1-CAF
Drug Name

Final
(M)

hM1-2D

EC50 Averaged Max StdDev Max % Final
% Response
Response
EC50 (M)

Averaged Max StdDev Max
% Response
% Response

Dasatinib

58.9E-9

80

0.58

9.4E-9

83.75

0.35

Mithramycin

157.6E-9

93

2.56

174.1E-9

89.32

0.56

Teniposide

74.7E-9

94

0.50

482.6E-9

89.59

1.74

Methylrosanilinium

499.3E-9

101

0.06

489.1E-9

93.04

0.98

Gemcitabine

1.7E-9

96

9.21E-3

760.6E-12

93.78

0.29

Dactinomycin

3.8E-9

99

0.67

1.7E-9

94.30

0.29

Aclarubicin

610.8E-9

96

0.30

475.1E-9

94.77

0.76

Emetine

182.3E-9

100

0.18

118.3E-9

94.99

0.33

Epirubicin
Daunorubicin

84.5E-9
38.8E-9

97
98

0.51
0.31

179.1E-9
100.4E-9

95.41
95.59

0.84
0.60

Homoharringtonine

17.1E-9

99

0.20

14.1E-9

96.16

0.31

Topotecan

32.6E-9

97

0.08

312.8E-9

96.72

0.81

Idarubicin

10.7E-9

97

0.34

72.2E-9

96.85

0.51

Doxorubicin

90.6E-9

100

0.15

181.6E-9

96.89

1.07

Disulfiram
Dipyrithione
magnesium sulfate
Bortezomib

184.8E-9

59

12.08

316.6E-9

97.93

1.01

459.6E-9

93

6.61

428.8E-9

98.97

0.18

1.4E-9

99

0.13

2.3E-9

99.25

0.14

Carfilzomib

2.6E-9

101

0.13

4.E-9

99.39

0.06

Romidepsin

952.8E-12

100

0.11

701.E-12

99.55

0.10

Auranofin
Phanquinone
Thiram
Tyrothricin
Afatinib
Neratinib

684.E-9
310.3E-9
596.4E-9
407.2E-9
2.8E-6
5.E-6

99
99
82
101
94
34

0.21
1.14
7.34
9.98E-3
3.05
6.04

400.9E-9
105.8E-9
386.8E-9
491.5E-9
226.3E-9
516.3E-9

99.55
99.68
100.10
100.92
78.23
67.78

0.07
0.22
0.07
0.09
2.26
1.49

Trametinib

5.E-6

38

5.35

2.7E-9

70.89

0.65

Oxaliplatin

5.E-6

11

2.82

5.E-6

10.49

2.86

Fluorouracil

5.E-6

33

9.34

5.E-6

45.58

2.18

Leukapheresis was performed to collect PBMCs, which
were used as a source of stimulator (dendritic) cells and
responder T cells. PBMCs were depleted of CD25+ T
cells (Miltenyi Biotec Inc.) to eliminate regulatory T
cells, and stimulated twice for seven days with autologous
DC pulsed with PCAA peptide. DC stimulations were
supplemented with IL-21 (30 ng/mL) on Day 1 and
restimulated on Day 8 with IL-2 (10 U/ml) and IL-7 (10
ng/ml). Cultures that contained ≥ 5% tetramer+ CD8+
T cells were sorted using a clinical grade cell sorter
(Miltenyi Nanosorter) and expanded twice using the Rapid
www.oncotarget.com

Expansion Protocol [31]. The total production time was
6 weeks. Antigen-specificity was evaluated by testing
against peptide-pulsed and antigen+ tumor targets. CTL
were successfully expanded for one of the three peptides
epitopes identified by targeted MS/MS. The purity and
phenotype of the CTL product was defined immediately
prior to infusion.
The PCAA-specific CTL line generated from patient
peripheral blood specifically lysed PCAA-peptide pulsed
targets; furthermore, robust and specific CTL killing of
patient autologous tumor as well as an HLA-matched
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PCAA+ tumor line was observed, suggesting that the
Yee lab had isolated a CTL line of relatively high affinity,
that the tumor expressed pMHC for the PCAA epitope of
sufficient density, and that such a line may exhibit tumor
rejection potential following adoptive transfer. The peptide
target that generated T-cells against for the patient was an
HLA-A*0101-restricted peptide derived from a protein
product of the gene VGLL1 (gene name = “Vestigial-like
1”).

reactive, antigen-specific T cells from patient peripheral
blood. Isolation and expansion of such T cells for adoptive
transfer was feasible, and the transferred T cells achieved
relatively high frequency in the peripheral blood, with
apparent enrichment in the pleural effusion, where they
were detected at high frequency more than a month
later. The lack of a significant clinical response may be
attributable to a failure of T cells to infiltrate into the lung
tissue and, notably, the loss of significant levels of the
target antigen following adoptive transfer. Combination
strategies to facilitate tumor infiltration and multivalent
targeting (including antigen-spreading and targeting
multiple antigens) may enhance clinical efficacy in future
studies.

Clinical protocol and course:
Under the protocol, the patient received CY (300mg/
m2 iv) on Day -2 and then an infusion of 1010 polyclonal,
IL-21 primed antigen-specific CTL/m2, immediately
followed by low-dose s.c. IL-2 and PD1 blockade (3mg/kg
every 2 weeks x 16 doses) [32]. Radiologic responses were
evaluated according to the mWHO-based irRC Criteria
[33]. The patient received an infusion of T cells (1010 cells
/m2: total 19 billion PCAA, pancreatic cancer associated
antigen-specific CTL) 30 days apart, each followed by
low-dose subcutaneous (s.c.) IL-2 (250,000 U/m2 every
12h) and anti-PD1 every 3 weeks. The T-cell infusion
was preceded by low-dose cyclophosphamide (CY)
conditioning (300 mg/m2 x 1) and followed by a two-week
course of low-dose subcutaneous IL-2. Although the entire
regimen could be administered in the ambulatory setting,
he was hospitalized for monitoring of potential cellinfusion-associated adverse events (AEs). No serious AEs
were observed apart from expected transient (<24 hours)
culture-negative fevers (≥38.3ºC), associated with CTLinduced cytokine release syndrome, and lymphopenia
lasting 10 days [34].

The T-cell receptor DNA sequence representations
of cells from the tumor, the leukapheresis, and the
selected amplification of T-cells
Samples of the pancreatic adenocarcinoma were
taken from the metastatic tumor in the left lung extracted
by thorascopic wedge resection in November 2013 for
DNA sequencing of the genome, DNA sequencing of
the T-cell receptor variable regions of the beta chain of
the receptor (Figure 20, sample 2, blue points are each
a different expanded clone sequence from the tumor) the
production of organoids in cell culture, and patient derived
murine xenografts. In Oct. 2015, T-cells from the patient
were obtained by leukapharesis and a sample was obtained
to sequence the variable regions of the beta chain of the
T-cell receptor (Figure 20, orange points). The points
(blue and orange) in the upper right-hand corner are clonal
sequence counts (100 to 1,000 reads) in common with the
tumor and the leukapharesis.
Some T-cell receptor sequences are common to all
individuals with the same HLA class 1 types (so-called
public sequences) so these clones, with high numbers of
DNA sequence reads in both samples 1 and 2 of Figure
20, do not necessarily mean detection of the same tumor
antigen by an expanded DNA sequence clone in both the
tumor and the blood. In October 2015, the leukapharesis
sample (sample 2 of Figure 21) and the T-cell products
that were expanded by a peptide (sample 1, Figure 21)
were sequenced for the beta chain T-cell receptor variable
region and compared. The clones in the upper right corner
of the graph are found in both samples. It is notable that
four blue clones (from the sample 1, T-cell product) are
present in 10,000 copies, two of which are found in 10100 copies in the leukapharesis sample 2 counts and two
in 1,000-10,000 copies in sample 2 leukaphares sample.
Figure 22 provides the direct comparison of T-cell clone
sequences shared by the T-cell peptide expanded clones
and the clones found in the original tumor two years
previously (Figure 22, blue clones). Two blue clones
with 10,000 sequence reads in the T-cell product have

Persistence, clonality, phenotype, and function of
monoclonal and polyclonal CTL in vivo
Transferred T cells were tracked by TCR sequence
analysis. High-throughput T cell receptor V beta
sequencing (HTTCS) was used to identify individual
clonotypes within CTL products, and track them in vivo
post-infusion in both peripheral blood, pleural effusion,
and lung biopsy samples. T cell receptor V beta analysis of
the T cell product, which was > 95% tetramer positive for
the target antigen, revealed that 99% of the TCR sequences
were restricted to 21 clonotypes, the dominant clone,
representing 43% of all sequences. HTTCS tracking of
peripheral blood samples revealed a cumulative frequency
(representing all 21 clonotypes) of 1.7% of total T cells in
the PBMC with the dominant clonotype comprising more
than 1% of total T cells. One month later, the transferred
antigen-specific T cells were present at very low but
detectable levels (.03%) in the periphery; however they
had accumulated in the pleural effusion biopsy (0.37%).
No infiltration into the lung tumor tissue was detected.
Overall, these results suggest that a relevant
tumor-associated antigenic epitope could be identified
from the patient tumor sample, and was of sufficient
immunogenicity to elicit autologous pancreatic tumorwww.oncotarget.com
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100-1,000 reads in the tumor. This does suggest that the
T-cell preparation that was infused into the patient in 2015
did contain a few clones with receptor sequences shared
between the tumor and the expanded T-cell component and
possibly targeting neoantigens in the tumor.
After the infusion of T-cells into the patient,
(October 20, 2015) the patient continued to have tumor
growth in the lung, as evidenced by increased tumor DNA
markers in the blood, increased size of the lung lesions
by imaging, and continued respiratory failures, although
each of these observations could have been due to either
an increased tumor load or a strong inflammation, killing
cells in the tumor. A biopsy of the lung tumor at this
time showed tissue sections with a small cell lung cancer
phenotype. DNA sequencing of that biopsy material
indicated that the tumor was derived from the original
adenocarcinoma of the pancreas (both the RAS mutation
and the p53 mutation at codon 175 were identical in both
the pancreatic carcinoma and the small cell like lung
cancer, as were other mutations found in the original tumor
in 2013).The autopsy materials obtained in January 2016
showed that tissue sections taken from many different
parts of the lung tumor had a small cell lung cancer
morphology (neuroendocrine-like), whereas other sections
taken from different parts of the tumor had a pancreatic
adenocarcinoma-like morphology, and some samples had
mixed morphologies, with both cell types. The simplest
interpretation of these observations is that a portion of
the tumor underwent an epithelial-mesenchyme transition
(EMT) giving rise to the small cell neuroendocrine-like
morphology. This epigenetic change altered the pattern
of gene expression and likely altered the neoantigens
expressed by the original pancreatic adenocarcinoma
tumor, giving rise to a failure of the T-cell therapy that was
attempted. The observation that the increased levels of the
Ras DNA biomarker sequence taken from the blood prior
to the October 2015 infusion of T-cells into the patient,
suggested that the EMT in the lung tumor began prior to
any immune-selection of the adenocarcinoma tumor cells
in the lung.
Whether the immune-selection actually worked to
kill the pancreatic adenocarcinoma cells, and possibly
to expand the neuroendocrine-like cells is unclear.
What is clear was that there was a prolonged (several
years) period of chemotherapy keeping the tumor
metastasis under control, and biopsies demonstrate that
this gives rise to increasing clonal heterogeneity of the
tumor, perhaps resulting in an EMT with epigenetic
changes and altered gene expression. Both genetic and
morphological heterogeneity of the lung tumor is clear
from the autopsy materials. This would be expected
to alter the immunological profile of possible tumor
antigens. Clearly, the tumor in vivo evolves under
therapeutic selections and there is a need for greater
monitoring and speed in understanding this evolution,
so that the therapeutic choices keep up with the tumor
www.oncotarget.com

evolution and heterogeneity. This applies to both the use
of immunological therapies and chemical therapies, which
were tested in organoids and mice carrying this tumor. In
the future, we will need accurate and rapid laboratory
processing of biopsy materials so as to respond to the
information collected from the tumor in real time.
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